ProQR Therapeutics NV (ProQR Therapeutics NV) FCF Margin % : -180.40% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is ProQR Therapeutics NV FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ProQR Therapeutics NV's Free Cash Flow for the three months ended in Dec. 2023 was $-6.46 Mil. ProQR Therapeutics NV's Revenue for the three months ended in Dec. 2023 was $3.58 Mil. Therefore, ProQR Therapeutics NV's FCF Margin % for the quarter that ended in Dec. 2023 was -180.40%.

As of today, ProQR Therapeutics NV's current FCF Yield % is 13.27%.

The historical rank and industry rank for ProQR Therapeutics NV's FCF Margin % or its related term are showing as below:

PRQR' s FCF Margin % Range Over the Past 10 Years
Min: -1985.34 Med: -1925.98 Max: 309.73
Current: 303.19

During the past 12 years, the highest FCF Margin % of ProQR Therapeutics NV was 309.73%. The lowest was -1985.34%. And the median was -1925.98%.

PRQR's FCF Margin % is ranked better than
98.85% of 1041 companies
in the Biotechnology industry
Industry Median: -141.21 vs PRQR: 303.19

ProQR Therapeutics NV FCF Margin % Historical Data

The historical data trend for ProQR Therapeutics NV's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV FCF Margin % Chart

ProQR Therapeutics NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,985.34

-1,925.98

309.73

ProQR Therapeutics NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-2,474.05	6,810.13	-882.77	-572.85	-180.40

Competitive Comparison of ProQR Therapeutics NV's FCF Margin %

For the Biotechnology subindustry, ProQR Therapeutics NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProQR Therapeutics NV's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's FCF Margin % falls into.

ProQR Therapeutics NV FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ProQR Therapeutics NV's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	22.003	/	7.104
	=	309.73 %

ProQR Therapeutics NV's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-6.46	/	3.581
	=	-180.40 %

ProQR Therapeutics NV FCF Margin % Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ProQR Therapeutics NV (ProQR Therapeutics NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (NAS:PRQR) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

0PQ:Germany

Address

Zernikedreef 9, Leiden, ZH, NLD, 2333 CK

Website

https://www.proqr.com

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.